Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature.
Celiac disease (CD) is an autoimmune disorder that occurs in genetically susceptible individuals of all ages and is triggered by immune response to gluten and related proteins. The disease is characterized by the presence of HLA-DQ2 and/or -DQ8 haplotypes, diverse clinical manifestations, gluten-sensitive enteropathy, and production of several autoantibodies of which endomysial, tissue transglutaminase, and deamidated gliadin peptide antibodies are considered specific. Although antireticulin antibodies (ARA) have historically been used in the evaluation of CD, these assays lack optimal sensitivities and specificities for routine diagnostic use. This minireview highlights the advances in CD-specific serologic testing and the rationale for eliminating ARA from CD evaluation consistent with recommendations for diagnosis.
Department of Pathology, University of Utah, Salt Lake City, UT, USA.
Sarada L
SL
Nandiwada
Anne E
AE
Tebo
D001323:Autoantibodies / Q000097:blood*; D002446:Celiac Disease / Q000175:diagnosis*; D019204:GTP-Binding Proteins / Q000276:immunology; D005903:Gliadin / Q000276:immunology; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012155:Reticulin / Q000276:immunology*; D012698:Serologic Tests / Q000379:methods; D011503:Transglutaminases / Q000276:immunology
D001323:Autoantibodies; D012155:Reticulin; D005903:Gliadin; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins